Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib with Standard of Care for Uncomplicated Malaria
NCT02614404Phase 1Completed
- Sponsor
- HuLow Medical
- Start
- Nov 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of imatinib in Plasmodium falciparum malaria (2 arms), sponsored by HuLow Medical. Primary endpoints: Time to Parasite Clearance at 5 days and 28-day Cure Rate. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT02614404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614404.